002252:SZSEShanghai RAAS Blood Products Co., Ltd. Analysis
Data as of 2026-08-21 - not real-time
CN¥4.84
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Shanghai RAAS Blood Products Co., Ltd. trades at ¥4.84, with its moving averages tangled rather than clearly stacked — a neutral trend structure. Across the trailing 30 sessions it gained 5.7%. Momentum indicators put RSI at 43.6 (neutral) with MACD reading bearish. Price has been bracketed by support at ¥4.80 and resistance at ¥5.28.
Valuation screens as undervalued: a P/E of 23.0 sits below the sector average of 30.7. Revenue is contracting at 24.7% on a 19.4% profit margin. The 1.62% dividend yield looks covered by current payout levels.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 34.0%, a beta of 0.15 and a maximum drawdown of 40.0%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 3/10 conviction.
Valuation screens as undervalued: a P/E of 23.0 sits below the sector average of 30.7. Revenue is contracting at 24.7% on a 19.4% profit margin. The 1.62% dividend yield looks covered by current payout levels.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 34.0%, a beta of 0.15 and a maximum drawdown of 40.0%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 3/10 conviction.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Trading below the 200-day average of 5.80
- MACD momentum is negative
- 30-day price change of +5.7%
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 23.0 versus sector average of 30.7
- Trading below the 200-day average of 5.80
- MACD momentum is negative
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 23.0 versus sector average of 30.7
- Profit margin of 19.4% is healthy
- Revenue contracting at -24.7%
Key Metrics & Analysis
Financial Health
Revenue Growth-24.70%
Profit Margin19.36%
P/E Ratio23.0
ROE4.08%
ROA2.34%
Debt/Equity12.16
P/B Ratio1.0
Op. Cash FlowCN¥-943675072
Free Cash FlowCN¥-1663556608
Industry P/E30.7
Technical Analysis
TrendNeutral
RSI43.6
SupportCN¥4.80
ResistanceCN¥5.28
MA 20CN¥5.03
MA 50CN¥4.85
MA 200CN¥5.80
MACDBearish
VolumeStable
Fear & Greed Index92.84
Valuation
GradeUndervalued
TypeValue
Dividend Yield1.62%
Risk Assessment
Beta0.15
Volatility34.01%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.